These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28306616)

  • 1. Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.
    Yoshimura Y; Takeda T; Kishi Y; Harada T; Nomura A; Washida K; Yoshimura B; Sato K; Yada Y; Aoki S
    J Clin Psychopharmacol; 2017 Jun; 37(3):296-301. PubMed ID: 28306616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
    Sacristán JA; Gómez JC; Montejo AL; Vieta E; Gregor KJ
    Clin Ther; 2000 May; 22(5):583-99. PubMed ID: 10868556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
    Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
    Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients.
    Hatta K; Kawabata T; Yoshida K; Hamakawa H; Wakejima T; Furuta K; Nakamura M; Hirata T; Usui C; Nakamura H; Sawa Y
    Gen Hosp Psychiatry; 2008; 30(4):367-71. PubMed ID: 18585542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone.
    Hatta K; Otachi T; Sudo Y; Kuga H; Takebayashi H; Hayashi H; Ishii R; Kasuya M; Hayakawa T; Morikawa F; Hata K; Nakamura M; Usui C; Nakamura H; Hirata T; Sawa Y;
    Psychiatry Res; 2012 Jul; 198(2):194-201. PubMed ID: 22421064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
    Tunis SL; Faries DE; Nyhuis AW; Kinon BJ; Ascher-Svanum H; Aquila R
    Value Health; 2006; 9(2):77-89. PubMed ID: 16626411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study.
    Yoshimura Y; Takeda T; Kishi Y; Harada T; Nomura A; Washida K; Yoshimura B; Sato K; Yada Y; Aoki S
    Int Clin Psychopharmacol; 2018 May; 33(3):147-154. PubMed ID: 29406406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.
    Wang HH; Cai M; Wang HN; Chen YC; Zhang RG; Wang Y; McAlonan GM; Bai YH; Wu WJ; Guo L; Zhang YH; Tan QR; Zhang ZJ
    J Psychiatr Res; 2017 Feb; 85():59-65. PubMed ID: 27837658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.
    Noordsy DL; Glynn SM; Sugar CA; O'Keefe CD; Marder SR
    J Psychiatr Res; 2017 Dec; 95():299-307. PubMed ID: 28942217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia.
    Suzuki Y; Sugai T; Ono S; Sawamura K; Fukui N; Watanabe J; Tsuneyama N; Saito M; Someya T
    Psychiatry Clin Neurosci; 2014 May; 68(5):353-6. PubMed ID: 24405493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
    Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
    Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study].
    Sacristán JA; Gómez JC; Ferre F; Gascón J; Pérez Bravo A; Olivares JM
    Actas Esp Psiquiatr; 2001; 29(1):25-32. PubMed ID: 11333516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study.
    Lambert M; Conus P; Schimmelmann BG; Eide P; Ward J; Yuen H; Schacht M; Edwards J; Naber D; McGorry PD
    Pharmacopsychiatry; 2005 Sep; 38(5):206-13. PubMed ID: 16189747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
    Einarson TR; Pudas H; Goswami P; van Impe K; Bereza BG
    J Med Econ; 2016; 19(2):111-20. PubMed ID: 26414966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
    Walther S; Moggi F; Horn H; Moskvitin K; Abderhalden C; Maier N; Strik W; Müller TJ
    J Clin Psychopharmacol; 2014 Feb; 34(1):124-8. PubMed ID: 24346752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels.
    Mauri MC; Maffini M; Di Pace C; Reggiori A; Paletta S; Moliterno D; Rovera C; Altamura CA
    Int J Psychiatry Clin Pract; 2015 Jun; 19(2):99-105. PubMed ID: 25547438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan.
    Liu CY; Chiu NY; Wu CK; Yuan LM; Hsiao MC; Liao O
    Int Clin Psychopharmacol; 2003 Jan; 18(1):49-51. PubMed ID: 12490775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
    Uchida H; Mamo DC; Pollock BG; Suzuki T; Tsunoda K; Watanabe K; Mimura M; Bies RR
    Ther Drug Monit; 2012 Apr; 34(2):182-7. PubMed ID: 22377743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
    Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
    J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.